Rankings
▼
Calendar
KROS (Keros Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena
KROS
Keros Therapeutics, Inc.
Mkt Cap
$414M
Healthcare
·
Biotechnology
·
🇺🇸 United States
·
NASDAQ
Revenue (TTM)
$244M
Net Income (TTM)
$87M
EPS (TTM)
$2.30
Free Cash Flow (TTM)
$106M
Gross Margin
99.5%
Op. Margin
27.7%
Net Margin
35.7%
FCF Margin
43.4%
P/S Ratio (TTM)
1.7x
P/E Ratio (TTM)
4.8x
YoY Rev Growth
+6775.0%
Employees
—
Earnings Reports
▶
Q4 2025
NEW
Browse All Reports
Quarterly
FY
Revenue & Profitability
Revenue
Gross Profit
Operating Income
Quarter
Revenue
Gross Profit
Op. Income
Q1 23
$0
$0
-$39M
Q2 23
$0
$0
-$41M
Q3 23
$8K
-$543K
-$43M
Q4 23
$143K
$143K
-$46M
Q1 24
$83K
$83K
-$48M
Q2 24
$37K
$37K
-$50M
Q3 24
$388K
$74K
-$59M
Q4 24
$3M
$3M
-$53M
Q1 25
$211M
$211M
$152M
Q2 25
$18M
$18M
-$40M
Q3 25
$14M
$14M
-$15M
Q4 25
$385K
$0
-$29M
marketcaparena.com
Valuation
P/S Ratio
P/E Ratio
Quarter
P/S
P/E
Q1 23
—
—
Q2 23
—
—
Q3 23
51735.5x
—
Q4 23
2741.0x
—
Q1 24
1768.7x
—
Q2 24
1527.2x
—
Q3 24
635.8x
—
Q4 24
116.6x
—
Q1 25
1.9x
98.3x
Q2 25
1.8x
22.0x
Q3 25
1.7x
6.4x
Q4 25
1.7x
4.8x
marketcaparena.com
Operating Cash Flow
Operating Cash Flow
Free Cash Flow
Quarter
Operating CF
Free CF
Q1 23
-$34M
-$35M
Q2 23
-$31M
-$31M
Q3 23
-$34M
-$35M
Q4 23
-$25M
-$26M
Q1 24
-$45M
-$46M
Q2 24
-$40M
-$40M
Q3 24
-$31M
-$31M
Q4 24
-$46M
-$46M
Q1 25
$161M
$161M
Q2 25
-$30M
-$30M
Q3 25
$3M
$3M
Q4 25
-$27M
-$27M
marketcaparena.com
Capital Expenditures
CapEx
Quarter
CapEx
Q1 23
$1M
Q2 23
$311K
Q3 23
$550K
Q4 23
$541K
Q1 24
$946K
Q2 24
$310K
Q3 24
$386K
Q4 24
$289K
Q1 25
$565K
Q2 25
$720K
Q3 25
$132K
Q4 25
$134K
marketcaparena.com
OpEx vs Revenue Growth (YoY)
Revenue Growth
OpEx Growth
Quarter
Revenue Growth
OpEx Growth
Q1 23
—
+61.1%
Q2 23
—
+34.5%
Q3 23
—
+54.7%
Q4 23
—
+45.8%
Q1 24
—
+24.9%
Q2 24
—
+22.1%
Q3 24
+4750.0%
+36.4%
Q4 24
+2027.3%
+20.8%
Q1 25
+254413.3%
+21.9%
Q2 25
+49002.7%
+14.9%
Q3 25
+3575.8%
-49.8%
Q4 25
-87.3%
-47.3%
marketcaparena.com
Stock-Based Compensation
SBC ($)
% of Revenue
Quarter
SBC ($)
% of Revenue
Q1 23
$6M
—
Q2 23
$0
—
Q3 23
$0
0.0%
Q4 23
$7M
5121.7%
Q1 24
$8M
9722.9%
Q2 24
$9M
23743.2%
Q3 24
$9M
2272.4%
Q4 24
$9M
302.4%
Q1 25
$9M
4.2%
Q2 25
$9M
47.0%
Q3 25
$4M
27.9%
Q4 25
$7M
1897.4%
marketcaparena.com
OpEx Breakdown
R&D
G&A
SG&A
Quarter
R&D
G&A
SG&A
Q1 23
$31M
$8M
—
Q2 23
$33M
$9M
—
Q3 23
$34M
—
$9M
Q4 23
$37M
$9M
—
Q1 24
$38M
$10M
—
Q2 24
$41M
$10M
—
Q3 24
$49M
$10M
—
Q4 24
$46M
$11M
—
Q1 25
$49M
$10M
—
Q2 25
$44M
$14M
—
Q3 25
$20M
$10M
—
Q4 25
$18M
$12M
—
marketcaparena.com
Revenue Segments
License
Service, Other
Service
Quarter
License
Service, Other
Service
Q1 23
$144M
—
—
Q2 23
$144M
—
—
Q1 24
—
$83K
—
Q2 24
—
$37K
—
Q3 24
—
—
$400K
Q1 25
$195M
$16M
—
Q2 25
—
$18M
—
Q3 25
$10M
$4M
—
Q4 25
—
$385K
—
marketcaparena.com
War Chest
Cash & Equivalents
Short-Term Investments
Quarter
Cash
Short-term Investments
Total
Q1 23
$351M
$0
$351M
Q2 23
$322M
$0
$322M
Q3 23
$288M
$0
$288M
Q4 23
$331M
$0
$331M
Q1 24
$442M
$0
$442M
Q2 24
$406M
$0
$406M
Q3 24
$531M
$0
$531M
Q4 24
$560M
$0
$560M
Q1 25
$721M
$0
$721M
Q2 25
$690M
$0
$690M
Q3 25
$693M
$0
$693M
Q4 25
$287M
$0
$287M
marketcaparena.com
Shares Outstanding
Shares Outstanding
Quarter
Shares (Diluted)
QoQ Change
Q1 23
28M
+3.8%
Q2 23
30M
+4.3%
Q3 23
30M
+0.2%
Q4 23
30M
+1.5%
Q1 24
29M
-2.3%
Q2 24
36M
+22.6%
Q3 24
36M
-0.0%
Q4 24
40M
+11.7%
Q1 25
41M
+1.7%
Q2 25
41M
-1.0%
Q3 25
41M
+0.0%
Q4 25
38M
-6.8%
marketcaparena.com
Revenue Per Employee
Revenue / Employee
Year
Revenue/Employee
Employees
FY 18
—
—
FY 19
—
—
FY 20
$0
35
FY 21
$335K
60
FY 22
$0
105
FY 23
$1K
105
FY 24
$21K
169
FY 25
$7K
33K
marketcaparena.com